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Background: A study was conducted to evaluate and compare the efficacy of selamectin, spinosad, and
spinosad/milbemycin oxime against the KS1 strain of Ctenocephalides felis on dogs.
Methods: Forty-eight dogs were selected for the study and two batches of 24 were blocked and allocated
randomly to treatment groups and flea count times. There were four treatment groups of 12 dogs each: negative
control, topical selamectin, oral spinosad/milbemycin oxime, and oral spinosad. Each dog was infested with 100
fleas on Days −2, 7, 14, 21 and 28. Within each treatment group, six dogs were flea counted at 24 hours and six at
48 hours after treatment or post-infestation. On Day 0, dogs received a single treatment of the appropriate drug
according to the approved commercial label.
Results: Efficacy of selamectin against an existing flea infestation was 60.4% and 91.4% at 24 and 48 hours,
respectively, whereas spinosad/milbemycin oxime and spinosad were 100% at both time points. All products
were >90% effective within 24 hours after subsequent infestations on Days 7, 14 and 21. Following the Day 28 flea
infestation, selamectin was 93% and 95.7% effective at 24 and 48 hours, respectively. Whereas the efficacy of
spinosad/milbemycin oxime following the day 28 infestation was 84.7% and 87.5% at 24 and 48 hours, respectively
and spinosad alone was 72.9% and 76.3% effective at 24 and 48 hours, respectively.
Conclusions: After initial application, the two oral spinosad products had a more rapid onset of flea kill than
topical selamectin which took up to 48 hours to control (>90%) the existing infestation. However, for subsequent
weekly flea infestations selamectin had similar or better efficacy than spinosad or spinosad/milbemycin oxime at 24
and 48 hours after infestation. Spinosad/milbemycin oxime and spinosad were >90% effective against the KS1 strain
from Day 1 to Day 23. Whereas, selamectin was >90% effective against the KS1 strain of C. felis from Day 2 to Day 30.
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Fleas are clinically important parasites of domestic pets
being responsible for the production of allergic dermatitis,
serving as vectors of various bacterial pathogens and are
the intermediate hosts for filarid and cestode parasites
and occasionally cause anemia and death [1,2]. When
evaluating the efficacy of a flea adulticide a veterinarian
needs to consider the initial speed of kill and residual
speed of kill of the product [3]. Initial speed of kill refers* Correspondence: Dryden@vet.k-state.edu
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reproduction in any medium, provided the orto how rapidly a product kills the existing flea population
on a pet once the product is administered. Initial speed of
kill is important to provide the pet rapid relief from the
existing infestation. Residual speed of kill refers to how
rapidly a product can kill newly acquired fleas days or
weeks after the product was administered [3,4]. When a
dog or cat enters premises with emerging fleas, it is
important to kill these fleas as rapidly as possible after
they jump on the pet. A residual flea adulticide that can
kill these newly acquired fleas quickly can likely decrease
the transmission of vector borne diseases, assist in the
management of flea allergy dermatitis, and reduce the
likelihood that fleas can survive long enough to produceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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important, the residual speed of kill of a product is critical
to the success of a flea control program.
The purpose of this study was to evaluate and compare
the initial and residual speed of kill of a selamectin topical
formulation, a spinosad/milbemycin oxime oral tablet and
spinosad only oral tablet against the KS1 Ctenocephalides
felis flea strain on dogs. The cat flea, C. felis is generally
the most common flea species parasitizing dogs
worldwide [2]. Both compounds being evaluated are
systemically active with selamectin being a topically
applied transdermally absorbed macrocyclic lactone with
broad-spectrum activity against numerous external and
internal parasites [5]. Spinosyns are a group of natural
products produced by fermentation of the actinomycete,
Saccharopolyspora spinosa. The two most abundant
components produced during the fermentation process
are Spinosyns A and D, which are the insecticidal active
components of orally administered spinosad [6]. The flea
strain that was used in this study was the KS1 cat flea
strain that has been maintained as a closed colony at
Kansas State University since 1990. This strain was selected
because previous studies have indicated that the KS1 strain
has some level of resistance or reduced susceptibility to a
variety of insecticides [4,7-12].
Methods
Animals and housing
Fifty four purpose bred mongrel dogs (28 m:26f) were
housed in individual runs. No drugs, baths, shampoos,
or pesticides were administered to the dogs during the
preconditioning phase or during the course of the study,
other than what was described in the protocol. All animal
care procedures conformed to guidelines established by
the Institutional Animal Care and Use Committee at
Kansas State University (IACUC # 3115). Physical exami-
nations were performed by a licensed veterinarian on all
dogs prior to enrollment into the study and all dogs
were determined to be healthy. Examinations included
evaluation of rectal temperature, thoracic auscultation,
skin and hair coat assessment, and the assessment of the
general physical condition of each dog.
Animal selection and randomization
Due to space restrictions, dogs were enrolled in two
separate batches: 28 in batch one and 26 in batch two.
On Day −7, dogs (7–8 months of age and 13.9-20.3 kg)
were infested with 100 adult cat fleas, C. felis, (KS1
strain) 1 to 5 days post emergence. On Day −6, flea
comb counts were performed to assess the ability of
dogs to maintain infestations. Dogs were combed with a
fine-toothed flea comb having 12–13 teeth/cm. The entire
dog and the entire length of the hair coat were combed
continuously for a minimum of 10 minutes. If <5 live fleaswere encountered in the first 10 minutes, combing was
terminated. If ≥5 live fleas were encountered in the first
10 minutes, the animal was combed for an additional
10 minutes.
The 24 dogs in each batch with the highest Day −6 flea
counts and that were deemed in good general health by
physical examination were selected. In each batch, dogs
were randomly assigned to treatments, times of flea
counts and pens using a randomized complete block
design with a two-way factorial structure. Treatment and
time of flea counts were the two factors and blocking was
done using the pre-treatment host suitability flea counts
on Day −6. Within blocks, animals were randomly
assigned to treatments and times of flea counts. Animals
within the same block were randomly assigned to pens
near each other. Personnel conducting flea combing and
flea counts were blinded to treatment groups.
Treatments
Treatment groups (12 dogs/group) were comprised of
non-treated controls (TO1), selamectin (6 – 12 mg/kg)
(RevolutionW; Pfizer Animal Health) topical solution
(TO2), spinosad (30 – 60 mg/kg) + milbemycin oxime
(0.5-1.0 mg/kg) (TrifexisW; Elanco) oral tablet (TO3) and
spinosad (30 – 60 mg/kg) (ComfortisW; Elanco) oral tablet
(TO4). Products were applied according to label directions
and dogs were observed following treatment for any
adverse events associated with the treatments.
Efficacy evaluations
To evaluate the ability of the formulations to eliminate
an existing flea infestation, all dogs were infested with
100 adult fleas on Day −2 and treatments were applied on
Day 0. Initial speed of kill was determined by removing
live fleas from 6 dogs in each treatment group at 24 hours,
and 6 dogs at 48 hours post-treatment. Residual activity
was determined by reinfesting dogs with 100 adult
fleas on Days 7, 14, 21 and 28 post-treatment and
then removing live fleas from 6 dogs in each treatment
group at 24 hours and 6 dogs at 48 hours post-
reinfestation. Fleas were removed using the previously
described flea combing procedure.
Data analysis
The individual animal was the experimental unit and all
treatment comparisons were carried out at the 5%
significance level (two-sided). The 24- and 48-hour flea
counts from the infestation of Day 7 onwards were log
(count +1) transformed prior to analysis and analyzed
using a general linear mixed model for repeated measures.
The statistical model included the fixed effects of
treatment, time of flea count, day of infestation and
all two- and three-way interactions. The random effects
included batch, block within batch, animal and residual.
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infestations were analyzed separately using a general linear
mixed model. The fixed effects were treatment, time of
flea count and treatment by time of flea count interaction
and the random effects were batch, block within batch
and residual. Back-transformed geometric least squares
means (GLSM), 95% confidence intervals, minimums and
maximums were calculated by treatment group, time of
flea count and day of infestation.
The% reduction in flea counts compared to respective
control at 24 hours and 48 hours after treatment and
each subsequent infestation for T02, T03, and T04 was
calculated as:
% reduction = 100 * [GLSM(T01) – GLSM(T0X)]/
GLSM(T01). If the treatment effect or any interaction
involving treatment was significant then the treatment
comparisons at each time of flea count and day of
infestation was conducted.
Results
Non-treated control dogs maintained adequate flea
infestations throughout the study with geometric mean
flea counts ranging from 24.40 to 51.46 (Table 1). The
spinosad-based formulations provided 100.0% efficacy
within 24 hours of treatment (Table 1). Selamectin
provided 60.4% and 91.4% efficacy with 24 and 48 -
hours of treatment, respectively. The efficacy 48 hours
after infestations on Days 7, 14 & 21 were equivalent
for all three products (Table 1). Following the Day 28
flea infestation selamectin was 93% and 95.7% effective at
24 and 48 hours, respectively. Whereas, the efficacy
of spinosad/milbemycin oxime following the Day 28
infestation was 84.7% and 87.5% at 24 and 48 hours,
respectively and spinosad alone was 72.9% and 76.3%
effective at 24 and 48 hours, respectively (Table 1).
There were no adverse events associated with treatments
in this study.
Discussion
This study demonstrated that the oral spinosad formula-
tions provided rapid initial speed of kill against the KS1
flea strain, with 100% efficacy within 24 hours of
treatment. However, the initial speed of kill of selamectin
was not as rapid; selamectin provided 60.4% and 91.4%
reductions in flea populations within 24 and 48 hours of
treatment, respectively.
The results for the spinosad formulations in this study
were similar to several previous studies where the efficacy
was also 100% within 24 hours of oral administration to
dogs [12-14]. The results for the speed of kill of selamectin
in this study are also comparable to previous studies
where efficacy ranged from 83.7% at 24 hours to 100% at
48 hours [15-17]. It is likely that the slower initial speed of
kill of selamectin as compared to spinosad is related tothe need to be absorbed across the skin to reach effective
blood levels.
While the initial speed of kill of selamectin was slower
than the spinosad formulations, the residual speed of kill
of selamectin against the KS1 flea strain was similar to
or better than the spinosad-based oral formulations.
The spinosad/milbemycin oxime- and spinosad-based
formulations were >90% effective against the KS1 strain
from Day 1 to Day 23. Whereas, selamectin was >90%
effective against the KS1 strain of from Day 2 to Day 30.
The residual speed of kill of selamectin in this study was
similar to that seen in previous studies. In two studies
the efficacy of selamectin on dogs 48 hours following
infestations on Day 28 ranged from 99.2% to 100% [16,18].
The residual speed of kill of spinosad in this study
contrasts with some previous reports. In a study where
dogs were fed and then given spinosad at the minimal
dose of 30 mg/kg, efficacy 48 hours after the Day 28
flea infestation ranged from 99.1-99.5% [6]. In a study
evaluating and comparing the spinosad and spinosad/
milbemycin oxime tablet formulations administered to
dogs, both formulations provided 100% efficacy 48 hours
after the Day 28 flea infestation [14]. However, in a
different study, the efficacy of spinosad administered to
dogs 24 and 48 hours after the Day 28 infestation was
85.0% and 89.0%, respectively [19]. These data are further
contrasted with two previous studies evaluating the
efficacy of spinosad using the KS1 flea strain where the
efficacy 24 hours after the Day 28 infestation was only
22.1% and 32.5% [12]. It is interesting to note that in the
current study using the same flea strain, the efficacy 24 -
hours following the Day 28 flea infestation was 72.9%
and 84.7% for the spinosad and spinosad/milbemycin
oxime formulations, respectively. It is unknown why this
difference in efficacy was seen between these two studies.
Several studies have demonstrated that the KS1 flea
strain has reduced susceptibility or outright resistance to
carbaryl, chlorpyriphos, fenthion, fipronil, imidacloprid,
permethrin, pyrethrins, and spinosad [4,7-12]. While these
insecticides have performed poorly as residual insecticides
against the KS1 strain, dinotefuran, metaflumizone
and selamectin topical spot-on formulations have
demonstrated excellent residual efficacy against this strain
[3,11,12,20]. The good residual efficacy of selamectin
against the KS1 flea strain was again demonstrated in this
current study.
While laboratory studies are important and often
necessary to evaluate and compare the efficacy of flea
products, the performance of the products under natural
in-home situations is equally important. A large scale
clinical field trial was conducted in the U.S. where
spinosad was administered orally to 330 dogs and
selamectin was applied topically to 140 dogs [21]. By Days
60 and 90 of the 3 month trial, the percent reduction in
Table 1 Geometric mean flea counts and percent efficacy relative to nontreated controls for dogs treated with a selamectin topical spot-on, a spinosad/milbemycin
oxime oral tablet or a spinosad only oral tablet
Day 0 Day 7 Day 14 Day 21 Day 28
Treatment1 Mean # of fleas2,3 % control4 Mean # of fleas % control Mean # of fleas % control Mean # of fleas % control Mean # of fleas % control
24 hours post-treatment or infestation
Non-treated Control 26.38a 46.39a 35.99a 28.85a 51.46a
Selamectin 10.45a 60.4 0.12b 99.7 1.52b 95.8 0.62b 97.9 3.62b 93.0
Spinosad-Milbemycin 0.00b 100.0 0.00b 100.0 0.12c 99.7 1.29b,c 95.5 7.85b 84.7
Spinosad 0.00b 100.0 0.00b 100.0 0.12c 99.7 2.19c 92.4 13.96b 72.9
48 hours post-treatment or infestation
Non-treated Control 36.25a 38.71a 24.40a 33.81a 30.81a
Selamectin 3.10b 91.4 0.00b 100.0 0.12b 99.5 0.12b 99.6 1.33b 95.7
Spinosad-Milbemycin 0.00c 100.0 0.00b 100.0 0.00b 100 0.41b 98.8 3.86b,c 87.5
Spinosad 0.00c 100.0 0.00b 100.0 0.26b 98.9 0.44b 98.7 7.31c 76.3
1 Each of 6 dogs in the control group received no treatment. Each of 6 dogs in the Selamectin topical spot-on, Spinosad/Milbemycin oxime oral tablet or a Spinosad only oral tablet groups were administered the
formulations according to label directions on Day 0.
2 Each dog was infested with 100 adult Ctenocephalides felis from the KS1 strain on days −2, 7, 14, 21 & 28.
3 Geometric mean # of fleas recovered from dogs per treatment group.
4% control = ((geometric mean count control -geometric mean count treatment)/ geometric mean count control)) × 100.
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spinosad-treated dogs and 97.9% and 98.9% for the
selamectin-treated dogs, respectively [21]. In another
three month clinical field trial conducted in France, the
percent reduction in flea numbers on the dogs on Days 60
and 90 were 99.6% and 99.6% for the spinosad-treated
dogs and 97.8% and 98.2% for the selamectin-treated dogs,
respectively [22]. Both these clinical field trials demon-
strated that selamectin and spinosad were highly effective
in eliminating flea infestations on client owned dogs.
Conclusions
Topically applied and systemically active selamectin
was ≥90% effective against the KS1 strain on dogs from
Day 2 to Day 30. Whereas, the oral spinosad/milbemycin
oxime tablet and spinosad only tablets provided ≥ 90% flea
reduction in KS1 flea populations on dogs from Day 1 to
Day 23. While the two oral spinosad products had a more
rapid onset of flea kill, the topical selamectin formulation
had similar or slightly better residual efficacy than
spinosad and spinosad/milbemycin oxime.
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